We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Rating & price-target changes
Stored first · Google News · Yahoo Finance (English)
BioAtla Shareholders Back Directors, Auditor and Pay Plan - TipRanks
BioAtla Shareholders Back Directors, Auditor and Pay Plan TipRanks
BioAtla Inc. (BCAB) Q4 2025 Earnings: Narrower Net Loss Surpasses Expectations as Clinical Pipeline Progresses - Basic EPS Analysis - dars.gov.et
BioAtla Inc. (BCAB) Q4 2025 Earnings: Narrower Net Loss Surpasses Expectations as Clinical Pipeline Progresses - Basic EPS Analysis dars.gov.et
BCAB Q4 2025 Earnings: Narrower-Than-Expected Loss Surprises Markets as Stock Declines - Tax Rate Impact - dars.gov.et
BCAB Q4 2025 Earnings: Narrower-Than-Expected Loss Surprises Markets as Stock Declines - Tax Rate Impact dars.gov.et
Enterprise value to EBIT forward of BioAtla, Inc. – NASDAQ:BCAB - TradingView
Enterprise value to EBIT forward of BioAtla, Inc. – NASDAQ:BCAB TradingView
Enterprise value to revenue forward of BioAtla, Inc. – NASDAQ:BCAB - TradingView
Enterprise value to revenue forward of BioAtla, Inc. – NASDAQ:BCAB TradingView
BioAtla, Inc. Actuals & Estimates (NASDAQ:BCAB) - TradingView
BioAtla, Inc. Actuals & Estimates (NASDAQ:BCAB) TradingView
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 06. | After market close (AMC) | — | — | — | — | — | Scheduled |
| FY2023 Q3 | 2022. 09. 30. | Time TBD | — | $-2.11 | — | — | $0 | Reported |
| FY2023 Q2 | 2022. 06. 30. | Time TBD | — | $-1.42 | — | — | $0 | Reported |
| FY2023 Q1 | 2022. 03. 31. | Time TBD | — | $-0.65 | — | — | $0 | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2025. 08. 13. | JMP Securities | — | Downgrade | Market Outperform → Market Perform | — | JMP Securities: Market Outperform → Market Perform |
| 2025. 03. 31. | Citizens Capital Markets | — | Maintain | Market Outperform → Market Outperform | — | Citizens Capital Markets: Market Outperform |
| 2025. 03. 31. | HC Wainwright & Co. | — | Maintain | Neutral → Neutral | — | HC Wainwright & Co.: Neutral |
| 2024. 11. 13. | HC Wainwright & Co. | — | Downgrade | Buy → Neutral | — | HC Wainwright & Co.: Buy → Neutral |
| 2024. 09. 16. | JMP Securities | — | Maintain | Market Outperform → Market Outperform | — | JMP Securities: Market Outperform |
| 2024. 05. 24. | JMP Securities | — | Maintain | Market Outperform → Market Outperform | — | JMP Securities: Market Outperform |
As of FY2026Q1 · Source: SEC/DART + price data
| # | Institution | Mandate | Shares | Value | Weight | Change | Position |
|---|---|---|---|---|---|---|---|
| 1 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 81,330 | $46.17K | 0.00% | — | New position |